source
- Electra Therapeutics raises $350M in IPO to fund pivotal immune-disease antibody developmentElectra Therapeutics announced an initial public offering that raised $350 million, exceeding its earlier target. The IPO consisted of 23.3 million shares sold at $15 per share, and underwriters w…
- Xenon shares plunge 23% after voluntary hold on psychiatry trials, despite filing NDA for epilepsy drugXenon Pharmaceuticals announced that its lead asset azetukalner (AZK) has been submitted to the FDA as a new drug application for focal onset seizures. At the same time, the company disclosed a vo…